Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional
ID: 359161Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359161
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative for the development of non-addictive analgesic therapeutics, specifically targeting small molecules and biologics to treat pain. This cooperative agreement aims to accelerate the discovery and optimization of promising therapeutic candidates, facilitating their readiness for Phase II clinical studies, while excluding basic research and clinical studies beyond Phase I. The program encourages collaborations among researchers with expertise in pain therapeutics development, with applications expected to be submitted by early 2026, and an estimated award date set for September 2026. For further inquiries, interested parties can contact Dr. Mohamed Hachicha at 301-496-1779 or via email at mohamed.hachicha@nih.gov.

    Point(s) of Contact
    Mohamed Hachicha, PhD National Institute of Neurological Disorders and Stroke
    (301) 496-1779
    mohamed.hachicha@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative for the development of non-addictive analgesic therapeutics, specifically targeting small molecules and biologics to treat pain. This cooperative agreement aims to accelerate the discovery and optimization of promising therapeutic candidates, facilitating their readiness for Phase II clinical studies, while excluding basic research and clinical studies beyond Phase I. The program encourages collaborations among researchers with expertise in pain therapeutics development, with applications expected to be submitted by early 2026, and an estimated award date set for September 2026. For further inquiries, interested parties can contact Dr. Mohamed Hachicha at 301-496-1779 or via email at mohamed.hachicha@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative's funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)." This initiative aims to support pilot projects that identify new druggable targets for pain by generating preliminary data on understudied proteins associated with pain management. The funding opportunity is particularly significant as it seeks to advance research in pain management and drug discovery, contributing to the broader goal of addressing the opioid addiction crisis. Eligible applicants can receive up to $100,000 for projects lasting one year, with applications due by July 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html.
    HEAL NOFO for the HEAL INTERACT Data Center
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a Notice of Funding Opportunity (NOFO) for the HEAL INTERACT Data Center, aimed at addressing musculoskeletal and peripheral pain through integrated research initiatives. This cooperative agreement seeks to fill knowledge gaps and identify novel research directions in the field, encouraging collaborative investigations among experts in pain mechanisms. While applications are not currently being solicited, potential applicants are urged to prepare meaningful collaborations and responsive projects, with an estimated synopsis post date of September 25, 2025, and a projected award date of August 3, 2026. For further inquiries, interested parties can contact Dr. Rebecca Lenzi at rebecca.lenzi@nih.gov or by phone at 301-408-7447.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at identifying new druggable targets for pain related to understudied proteins. This initiative invites pilot projects that focus on generating preliminary data on specific eligible proteins, particularly those with a PubMed score of less than 10, which are considered understudied and may lead to innovative pain treatments. The funding opportunity, which provides up to $100,000 for a one-year project, emphasizes the importance of diversity in applicant teams and requires coordination among grant recipients. Interested applicants should note that the application submission period begins on January 16, 2025, and clinical trials are not permitted under this grant. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-154.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: NIH-DOD-VA Pain Management Collaboratory � Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the HEAL Initiative, specifically targeting the NIH-DOD-VA Pain Management Collaboratory to support pragmatic and implementation science demonstration projects. This initiative aims to conduct large-scale clinical trials focusing on nonopioid pain management strategies and addressing opioid misuse among U.S. Veterans, military personnel, and their families. The funding opportunity, which will be structured as a cooperative agreement, is expected to provide approximately $850,000 for one award, with the NOFO anticipated to be published in Fall 2024 and applications due by November 2024. Interested applicants should prepare to develop collaborative projects that align with the goals of the Pain Management Collaboratory, with an estimated award date set for July 1, 2025.
    HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to release a Notice of Funding Opportunity (NOFO) titled "HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)" aimed at supporting research that translates addiction-related findings into practical applications to combat the opioid crisis and overdose events. This initiative seeks to identify and address factors influencing substance use and overdose deaths, focusing on developing effective, scalable interventions that integrate evidence-based practices into routine healthcare. Interested small businesses are encouraged to prepare for this opportunity, with applications expected to be solicited after the estimated synopsis post date of August 1, 2025, and closing on October 16, 2025. For further inquiries, potential applicants can contact Dr. Tisha Wiley at tisha.wiley@nih.gov or by phone at 301-594-4381.
    HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the HEAL Initiative: Pain Research Enhancement Program (PREP), a federal grant aimed at supporting pain research projects from R15-eligible institutions. This initiative seeks to promote rigorous basic and mechanistic pain research, foster interdisciplinary collaborations, and enhance the research environment for health professional trainees and students. The program is crucial for diversifying the pain research workforce and advancing understanding of pain mechanisms, with funding available up to $375,000 over a maximum three-year period. Applications will be accepted starting October 18, 2024, with a deadline of November 19, 2024, and interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Basic Experimental Studies with Humans (BESH) Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the HEAL Initiative PainCare Clinician Training Program (PCTP) through the Mentored Clinical Scientist Development Awards (K08), aimed at supporting early-career clinician-scientists focused on clinical pain research. This program seeks to develop independent investigators who will conduct basic experimental studies involving human participants, with a strong emphasis on innovating treatments for chronic pain, which affects over 25 million Americans. Awardees will receive funding of up to $125,000 per year for salary and an additional $50,000 for research development costs, with a commitment of at least 75% full-time effort required. Interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov, and the application deadline is July 12, 2027.